Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  ImmunoPrecise Antibodies Ltd.    IPA   CA45257F2008

IMMUNOPRECISE ANTIBODIES LTD.

(IPA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Tsx Venture Exchange
11/25/2020 11/26/2020 11/27/2020 11/30/2020 12/01/2020 Date
10.1(c) 10.01(c) 10.02(c) 9.7(c) 10.25 Last
28 873 22 347 29 435 34 395 45 959 Volume
-1.56% -0.89% +0.10% -3.19% +5.67% Change
More quotes
Financials
Sales 2021 20,0 M 15,4 M 15,4 M
Net income 2021 -1,75 M -1,35 M -1,35 M
Net Debt 2021 - - -
P/E ratio 2021 -121x
Yield 2021 -
Sales 2022 21,0 M 16,2 M 16,2 M
Net income 2022 -1,56 M -1,21 M -1,21 M
Net Debt 2022 - - -
P/E ratio 2022 -97,0x
Yield 2022 -
Capitalization 163 M 125 M 125 M
Capi. / Sales 2021 8,15x
Capi. / Sales 2022 7,74x
Nbr of Employees -
Free-Float 90,0%
More Financials
Company
Immunoprecise Antibodies Ltd, formerly Tanqueray Exploration Ltd, is a Canada-based supplier of custom hybridoma development services. The Company's geographical segments include United States of America and Canada. It offers products, such as antibodies and hybridoma licensing. It offers various services, such as ImmunoProtect, Monoclonal Development, Polyclonal Development, Antibody Protection, Peptide Production... 
More about the company
All news about IMMUNOPRECISE ANTIBODIES LTD.
11/26IMMUNOPRECISE ANTIBODIES : Ranked Number 240 Fastest-Growing Company in North Am..
AQ
11/25IMMUNOPRECISE ANTIBODIES : Ranked Number 240 Fastest-Growing Company in North Am..
AQ
11/24IMMUNOPRECISE ANTIBODIES : IPA Selects Polytope Formulations for Pre-Clinical St..
AQ
11/23IMMUNOPRECISE ANTIBODIES : IPA Selects Polytope™ Formulations for Pre-Clin..
AQ
11/20IMMUNOPRECISE ANTIBODIES : and Genmab Enter into a Technology Partnership Target..
AQ
11/19IMMUNOPRECISE ANTIBODIES : and Genmab Enter into a Technology Partnership Target..
AQ
11/17IMMUNOPRECISE ANTIBODIES : Confirms Effective Date of Share Consolidation
AQ
11/09IMMUNOPRECISE ANTIBODIES : Files Preliminary Base Shelf Prospectus and Registrat..
AQ
11/04IMMUNOPRECISE ANTIBODIES : to Complete Share Consolidation in Preparation for Po..
AQ
11/04IMMUNOPRECISE ANTIBODIES : and Mila Announce Strategic AI Partnership
AQ
11/03IMMUNOPRECISE ANTIBODIES : and Mila Announce Strategic AI Partnership
AQ
10/28IMMUNOPRECISE ANTIBODIES : and Twist Bioscience Announce Collaboration for the C..
AQ
10/27IMMUNOPRECISE ANTIBODIES : and Twist Bioscience Announce Collaboration for the C..
AQ
10/09IMMUNOPRECISE ANTIBODIES : IPA Delivers Lead Candidate Antibodies from B cell Se..
AQ
10/08IMMUNOPRECISE ANTIBODIES : IPA Delivers Lead Candidate Antibodies from B Cell Se..
AQ
More news
News in other languages on IMMUNOPRECISE ANTIBODIES LTD.

- No features available -

More news
Chart IMMUNOPRECISE ANTIBODIES LTD.
Duration : Period :
ImmunoPrecise Antibodies Ltd. Technical Analysis Chart | IPA | CA45257F2008 | MarketScreener
Technical analysis trends IMMUNOPRECISE ANTIBODIES LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 12,90 CAD
Last Close Price 9,70 CAD
Spread / Highest target 33,0%
Spread / Average Target 33,0%
Spread / Lowest Target 33,0%
EPS Revisions
Managers
NameTitle
Jennifer Bath President, Chief Executive Officer & Director
James S. Kuo Chairman
Lisa Helbling Chief Financial Officer
Yasmina Noubia Abdiche Chief Scientific Officer
Gregory S. Smith Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOPRECISE ANTIBODIES LTD.240.35%129
CSL LIMITED7.84%99 427
SAMSUNG BIOLOGICS CO.,LTD.81.52%46 940
BIOGEN INC.-19.06%36 958
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.151.53%30 386
ALEXION PHARMACEUTICALS, INC.14.50%26 723